Research
Hormonal
Sleep disruption is associated with an increased risk of metabolic syndrome, type-2 diabetes, and certain cancers through mechanisms involving altered gene expression, hormone levels, and immune response.
Prioritize sleep as much as you prioritize diet and exercise. Chronic sleep loss or irregular sleep schedules significantly increase your risk for metabolic syndrome, diabetes, and cancer. Consistent, adequate sleep is non-negotiable for long-term health.
GoodSupportsHIGH confidence
These changes in mice and humans include a significant reduction in the circadian regulation of transcription and translation and core clock genes in the periphery... point to the molecular mechanisms underlying the established adverse health outcomes associated with short sleep duration and shift work, such as metabolic syndrome and cancer.
Why this rating
Supported by epidemiological data and animal models reviewed.
Source
How sleep and wakefulness influence circadian rhythmicity: effects of insufficient and mistimed sleep on the animal and human transcriptome
Simon Archer et al. · Journal of Sleep Research · 2015
DOI 10.1111/jsr.12307
narrative_reviewCited 177×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Insufficient or mistimed sleep disrupts circadian gene expression rhythms in peripheral tissues (e.g., liver, blood), leading to metabolic and immune dysregulation, while the central pacemaker (SCN) remains largely unaffected.Good
- Mistimed sleep (sleeping during the day) causes a massive arrhythmicity in peripheral gene expression, with 97% of rhythmic genes becoming arrhythmic in humans.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →